Allianz SE raised its holdings in shares of Danaher Corporation (NYSE:DHR – Free Report) by 16.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 42,020 shares of the conglomerate’s stock after acquiring an additional 5,835 shares during the quarter. Allianz SE’s holdings in Danaher were worth $9,310,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also modified their holdings of the company. Prime Capital Investment Advisors LLC grew its position in Danaher by 0.5% during the 3rd quarter. Prime Capital Investment Advisors LLC now owns 9,203 shares of the conglomerate’s stock worth $2,039,000 after acquiring an additional 45 shares during the last quarter. Essential Investment Partners LLC increased its holdings in shares of Danaher by 34.6% in the third quarter. Essential Investment Partners LLC now owns 175 shares of the conglomerate’s stock worth $39,000 after acquiring an additional 45 shares in the last quarter. Montis Financial LLC increased its holdings in shares of Danaher by 2.3% in the third quarter. Montis Financial LLC now owns 2,020 shares of the conglomerate’s stock worth $448,000 after acquiring an additional 46 shares in the last quarter. Covestor Ltd raised its position in shares of Danaher by 28.3% during the third quarter. Covestor Ltd now owns 213 shares of the conglomerate’s stock worth $47,000 after purchasing an additional 47 shares during the period. Finally, Veery Capital LLC raised its position in shares of Danaher by 3.1% during the third quarter. Veery Capital LLC now owns 1,581 shares of the conglomerate’s stock worth $350,000 after purchasing an additional 48 shares during the period. 79.05% of the stock is currently owned by institutional investors and hedge funds.
Insider Activity
In other news, EVP Gregory Milosevich sold 2,100 shares of the business’s stock in a transaction that occurred on Monday, November 9th. The shares were sold at an average price of $230.62, for a total value of $484,302.00. Following the completion of the transaction, the executive vice president directly owned 22,367 shares in the company, valued at approximately $5,158,277.54. The trade was a 8.58% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CAO Christopher Bouda sold 7,598 shares of the company’s stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $234.56, for a total transaction of $1,782,186.88. Following the sale, the chief accounting officer directly owned 9,107 shares of the company’s stock, valued at approximately $2,136,137.92. This trade represents a 45.48% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. 10.80% of the stock is owned by company insiders.
Danaher Price Performance
Danaher (NYSE:DHR – Get Free Report) last released its quarterly earnings results on Wednesday, October 21st. The conglomerate reported $2.11 earnings per share for the quarter, beating the consensus estimate of $1.92 by $0.19. Danaher had a net margin of 16.91% and a return on equity of 11.17%. The firm had revenue of $6.55 billion for the quarter, compared to analysts’ expectations of $6.56 billion. During the same period in the prior year, the firm earned $1.89 EPS. The business’s revenue was up 8.3% on a year-over-year basis. Equities analysts forecast that Danaher Corporation will post 8.59 EPS for the current year.
Danaher Announces Dividend
The business also recently declared a quarterly dividend, which was paid on Friday, October 30th. Investors of record on Wednesday, September 30th were given a dividend of $0.40 per share. The ex-dividend date of this dividend was Wednesday, September 30th. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. Danaher’s dividend payout ratio is currently 26.19%.
Analyst Ratings Changes
DHR has been the subject of several research analyst reports. JPMorgan Chase & Co. boosted their price objective on Danaher from $250.00 to $270.00 and gave the company an “overweight” rating in a research report on Thursday, October 22nd. Weiss Ratings upgraded shares of Danaher from a “hold (c-)” rating to a “hold (c)” rating in a report on Wednesday, September 16th. Guggenheim upped their target price on shares of Danaher from $200.00 to $250.00 and gave the stock a “buy” rating in a research note on Thursday, October 1st. The Goldman Sachs Group reiterated a “buy” rating and set a $275.00 target price on shares of Danaher in a report on Thursday, October 22nd. Finally, Stifel Nicolaus lifted their price target on Danaher from $220.00 to $260.00 and gave the company a “buy” rating in a research note on Thursday, October 22nd. Eighteen investment analysts have rated the stock with a Buy rating and five have assigned a Hold rating to the company. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $242.91.
Check Out Our Latest Analysis on DHR
About Danaher
Danaher is a global science and technology company that develops and supplies products and services for biotechnology, life sciences, and diagnostics markets. Its offerings include instruments, reagents, consumables, software, and services used in research, drug development and manufacturing, and clinical testing. The company’s businesses include well-known brands such as Cytiva and Pall in bioprocessing and filtration, Beckman Coulter in laboratory and clinical diagnostics, Cepheid in molecular diagnostics, and Leica Microsystems in microscopy.
See Also
- Five stocks we like better than Danaher
- ZIM Just Posted Huge Profits, But Its $35 Buyout Is Still in Limbo
- Owens Corning’s Stock Slump May Have a Silver Lining for Dividend Investors
- The Patchpocalypse Could Be a Big Opportunity for These 2 Cybersecurity Stocks
- Anthropic’s Record IPO Could Ease a Major Concern for Broadcom Investors
Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Corporation (NYSE:DHR – Free Report).
Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.
